← Leaderboards
Eric K Rowinksy
Nanometics, Llc
$999,624
Attributed
$1,999,248
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $999.9K · FY2017–19$1M$750K$500K$250K$0
'17
'18
'19
Funding mix
By agency
NIH$1,999,248 · 1
By mechanism
R44$1,999,248 · 1
Top collaborators
- Steven Isaacman3 shared
Most similar at Nanometics, Llc
Same institution · by research overlap
- Steven Isaacman$10,967,667
- Andrew B Mahon$2,030,376
Others in their field
Other Emerging Leaders on “Dose”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$124,321,134
- Beth Baseler · Leidos Biomedical Research, Inc.$52,807,683
- Susan Abushakra · Alzheon, Inc.$47,265,244
- Paula Gonzalez-Maya · Fundacion Inciensa$37,578,679
- Xinhua Li · Nano Terra, Inc.$35,520,438
- Jeffrey Reich · Sparian Biosciences, Inc.$28,575,028
Research focus
DoseDose-LimitingAdverse EventBiological SciencesBiotechnologyAttenuationBullaBasal CellCapecitabineCell ProliferationChemotherapeutic AgentChemotherapyClinical DevelopmentClinically RelevantClinical ResearchClinical TrialsCommercial ApplicationCommercializationCoupledCreamCutaneousCytotoxicDiffusionDouble-Blind Method
Grant awards (3)
A Phase 2 clinical trial of topical uracil for the prevention of capecitabine induced hand-foot syndrome$999,333
R44 · FY2019 · CA
A Phase 2 clinical trial of topical uracil for the prevention of capecitabine induced hand-foot syndrome$1
R44 · FY2018 · CA
A Phase 2 clinical trial of topical uracil for the prevention of capecitabine induced hand-foot syndrome$999,914
R44 · FY2017 · CA